The FDA on Monday granted priority review of the investigational medication teprotumumab for treatment of thyroid eye disease, also known as Graves’ orbitopathy according to a press release from Horizon Therapeutics.
“Priority review for the teprotumumab [biologics license application] is another positive step toward our goal to make a difference in the lives of people who are living with active [thyroid eye disease] — a painful, debilitating and vision-threatening rare disease,” Timothy Walbert, chairman, president and CEO of Horizon Therapeutics, said in the release. “The
Uncategorized